<DOC>
	<DOCNO>NCT00038090</DOCNO>
	<brief_summary>Objective ass activity combination thalidomide dexamethasone patient previously untreated multiple myeloma .</brief_summary>
	<brief_title>Thalidomide-Dexamethasone Multiple Myeloma</brief_title>
	<detailed_description>This study examine potential efficacy thalidomide-dexamethasone treatment patient previously untreated multiple myeloma . - Thalidomide supply 50 mg capsule take mouth . - Thalidomide 200 mg daily evening bedtime increase 100-200 mg increment ( accord patient tolerability ) every 4 week . For elderly patient , poor performance status comorbid condition may affect tolerance thalidomide-dexamethasone combination , initial dose may reduce 50-100 mg decrement escalate weekly 50-100 mg increment tolerance . For patient experience significant toxicity ( &gt; grade 2 ) otherwise unable tolerate drug combination , dose reduce 50-100 mg decrement . For patient &gt; grade 2 toxicity , may necessary hold thalidomide dose improvement side effect subsequent resumption dose dose reduction outline . Dexamethasone 20mg/m2 morning breakfast day 1-4 , 9-12 , 17-20 , repeat cycle 1-2 week rest period . In case partial remission , maintenance treatment thalidomide alone continue long remission sustain dose free side effect . For patient achieve CR , consolidation thalidomide-dexamethasone 4-6 month follow follow-up without maintenance treatment . No maximum trial period plan . At relapse patient may reinitiated original thalidomide-pulse dexamethasone program respond patient may maintain thalidomide alone ( CR ) daily thalidomide dexamethasone ( day 1-4 ) relapse . Patients experience significant toxicity ( grade 2 ) time therapy receive low dose treatment interrupt . In attempt avoid deep venous thrombosis , patient anticoagulation contraindicate offer therapeutic anticoagulation ( INR 1.5-2.5 ) coumadin therapeutic dos low molecular weight heparin . Patients must willing return evaluation every 4 week since thalidomide may prescribe 28 day interval .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Previously untreated patient symptomatic progressive asymptomatic multiple myeloma . Criteria progression among patient asymptomatic disease include new lytic bone lesion , rise serum myeloma protein &gt; 5.0 gm/dl fall Hgb &lt; 10.5 gm/dl . Overt infection unexplained fever resolve treatment treat concurrently antibiotic . Patients must provide write informed consent indicate aware investigational nature study . Patients idiopathic monoclonal gammopathy stable asymptomatic myeloma ineligible . Patients whose prior therapy local radiotherapy alpha interferon eligible . Patients treat steroid order stabilize disease within 60 day prior enrollment eligible . Patients expose long period highdose glucocorticoid , exposure thalidomide alkylating agent ineligible .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Thalomid</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
</DOC>